Bristol Myers Squibb Reports Positive Phase 3 Trial Results for Lung Cancer Drug Iza-bren
Bristol Myers Squibb (BMY) announced positive Phase 3 trial results for its experimental cancer drug, izalontamab brengitecan (iza-bren), in treating non-small cell lung cancer (NSCLC). The study showed that iza-bren nearly doubled median progression-free survival to 11.1 months, compared to 5.7 months for patients receiving standard platinum-based chemotherapy. The drug was developed by SystImmune and tested via clinical trials administered by Sichuan Biokin Pharmaceutical in mainland China. While the efficacy data is highly encouraging, market reaction remained muted as investors weigh the necessity of additional multi-region confirmatory data to satisfy FDA and other Western regulatory standards for approval.
Tickers: $BMY
Topics: clinical trials non-small cell lung cancer oncology pharmaceuticals